novo nordisk eli lilly news

Novo Nordisk and Eli Lilly fall

Digest more

· 4h · on MSN

Eli Lilly vs Novo Nordisk: The 1 figure investors shouldn't ignore

The market for obesity drugs may soon reach almost $100 billion.

· 2d

Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

· 12d

Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog

· 18h

Hims offers cheapest GLP-1 weight-loss pill in US in a shock to Novo, Lilly

Online telehealth company Hims and Hers Health (HIMS.N) on Thursday began offering a much cheaper $49 compounded version of Novo Nordisk's (NOVOb.CO) new Wegovy weight-loss pill in a move that expands...

· 1d

Hims & Hers Launches Copy of Wegovy Pill, Prompting Legal Threats From Drugmaker Novo Nordisk

· 1d

VIEW Hims and Hers Health's compounded Wegovy pill offering fuels market jitters

2don MSN

Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar

Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit declining as much as 13% this year.

BioSpace

Novo Will Never Beat Lilly. Why Does It Have To?

Novo Nordisk and Eli Lilly have been battling head-to-head in an exploding obesity market. They should never have been compared apples to apples.

Eli Lilly rebounds on Q4 beat after Novo-led decline

Eli Lilly (LLY) stock rises after Q4 2025 earnings beat and strong 2026 outlook following a drop led by an underwhelming outlook from rival Novo (NVO). Read more here.

22hon MSN

Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings.

There's another fight brewing around GLP-1 drugs -- this time on the delivery side.